Olanzapine

Product NDC
67877-176
11-digit product format
678770176
Labeler code
67877
Product ID
67877-176_b4d4d6f0-2b78-4882-add2-7c6218270b7f
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Olanzapine
Dosage form
TABLET
Route
ORAL
Labeler
Ascend Laboratories, LLC
Application
ANDA202295
Marketing category
ANDA
Marketing start
2012-01-01
Substance
OLANZAPINE
Active strength
15 mg/1
Pharmacologic classes
Atypical Antipsychotic [EPC]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Additional Listing Data#

Finished product
Yes
Brand name base
Olanzapine
Listing expiration
2026-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
OLANZAPINE15 mg/1

Harmonized Identifiers#

Field, Values table
FieldValues
UniiN7U69T4SZR
Rxcui200034, 283639, 312077, 312078, 312079, 314154

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
42e9462d-db65-453b-8069-8fb2df9182e8Product name120211216
12d02c27-e8da-47f1-b815-ccca982731efProduct name920170802
877783eb-030c-6e3f-0979-804cf94d8856Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
67877-176-012022-10-31C16284748780-19d75b9d0-224b-f424-e053-dadaa90a57ceThese highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS. OLANZAPINE tablets, for oral use Initial U.S. Approval: 1996
67877-176-102022-10-31C16284748780-19d75b9d0-224b-f424-e053-dadaa90a57ceThese highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS. OLANZAPINE tablets, for oral use Initial U.S. Approval: 1996
67877-176-302022-10-31C16284748780-19d75b9d0-224b-f424-e053-dadaa90a57ceThese highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS. OLANZAPINE tablets, for oral use Initial U.S. Approval: 1996
67877-176-322022-10-31C16284748780-19d75b9d0-224b-f424-e053-dadaa90a57ceThese highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS. OLANZAPINE tablets, for oral use Initial U.S. Approval: 1996
67877-176-352022-10-31C16284748780-19d75b9d0-224b-f424-e053-dadaa90a57ceThese highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS. OLANZAPINE tablets, for oral use Initial U.S. Approval: 1996
67877-176-852022-10-31C16284748780-19d75b9d0-224b-f424-e053-dadaa90a57ceThese highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS. OLANZAPINE tablets, for oral use Initial U.S. Approval: 1996
67877-176-012020-01-31C16284748780-19d75b9d0-224b-f424-e053-dadaa90a57ceThese highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS. OLANZAPINE tablets, for oral use Initial U.S. Approval: 1996
67877-176-102020-01-31C16284748780-19d75b9d0-224b-f424-e053-dadaa90a57ceThese highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS. OLANZAPINE tablets, for oral use Initial U.S. Approval: 1996
67877-176-302020-01-31C16284748780-19d75b9d0-224b-f424-e053-dadaa90a57ceThese highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS. OLANZAPINE tablets, for oral use Initial U.S. Approval: 1996
67877-176-322020-01-31C16284748780-19d75b9d0-224b-f424-e053-dadaa90a57ceThese highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS. OLANZAPINE tablets, for oral use Initial U.S. Approval: 1996
67877-176-352020-01-31C16284748780-19d75b9d0-224b-f424-e053-dadaa90a57ceThese highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS. OLANZAPINE tablets, for oral use Initial U.S. Approval: 1996
67877-176-852020-01-31C16284748780-19d75b9d0-224b-f424-e053-dadaa90a57ceThese highlights do not include all the information needed to use OLANZAPINE TABLETS safely and effectively. See full prescribing information for OLANZAPINE TABLETS. OLANZAPINE tablets, for oral use Initial U.S. Approval: 1996

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
67877-176-01Olanzapine100 in 1 BOTTLETABLET10012
67877-176-10Olanzapine1000 in 1 BOTTLETABLET100012
67877-176-30Olanzapine30 in 1 BOTTLETABLET3012
67877-176-32Olanzapine7 in 1 BOTTLETABLET712
67877-176-33Olanzapine10 in 1 BLISTER PACKTABLET1012
67877-176-35Olanzapine10 in 1 CARTONTABLET1012
67877-176-85Olanzapine3 in 1 CARTONTABLET312

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
OLANZAPINEACTIVE INGREDIENTN7U69T4SZROLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
OLANZAPINEACTIVE MOIETYN7U69T4SZROLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
AMMONIAINACTIVE INGREDIENT5138Q19F1XOLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
BUTYL ALCOHOLINACTIVE INGREDIENT8PJ61P6TS3OLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
FD&C BLUE NO. 2INACTIVE INGREDIENTL06K8R7DQKOLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
FERRIC OXIDE REDINACTIVE INGREDIENT1K09F3G675OLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
FERROSOFERRIC OXIDEINACTIVE INGREDIENTXM0M87F357OLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
HYDROXYPROPYL CELLULOSE (TYPE H)INACTIVE INGREDIENTRFW2ET671POLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTEDINACTIVE INGREDIENT2165RE0K14OLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
ISOPROPYL ALCOHOLINACTIVE INGREDIENTND2M416302OLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
LACTOSE MONOHYDRATEINACTIVE INGREDIENTEWQ57Q8I5XOLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I30OLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
MANNITOLINACTIVE INGREDIENT3OWL53L36AOLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
PECTININACTIVE INGREDIENT89NA02M4RXOLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V3OLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
SHELLACINACTIVE INGREDIENT46N107B71OOLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
TALCINACTIVE INGREDIENT7SEV7J4R1UOLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JPOLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7
TRIACETININACTIVE INGREDIENTXHX3C3X673OLANZAPINE TABLET [ASCEND LABORATORIES, LLC]7

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
67877-176OLANZAPINE TABLET [ASCEND LABORATORIES, LLC]9Current NDC, Legacy NDC, 7 package rows20221101_e8626e68-088d-47ff-bf06-489a778815aa.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
314154OLANZapine 10 MG Oral TabletPSNe8626e68-088d-47ff-bf06-489a778815aa12
312077OLANZapine 15 MG Oral TabletPSNe8626e68-088d-47ff-bf06-489a778815aa12
200034OLANZapine 2.5 MG Oral TabletPSNe8626e68-088d-47ff-bf06-489a778815aa12
283639OLANZapine 20 MG Oral TabletPSNe8626e68-088d-47ff-bf06-489a778815aa12
312078OLANZapine 5 MG Oral TabletPSNe8626e68-088d-47ff-bf06-489a778815aa12
312079OLANZapine 7.5 MG Oral TabletPSNe8626e68-088d-47ff-bf06-489a778815aa12
314154olanzapine 10 MG Oral TabletSCDe8626e68-088d-47ff-bf06-489a778815aa12
312077olanzapine 15 MG Oral TabletSCDe8626e68-088d-47ff-bf06-489a778815aa12
200034olanzapine 2.5 MG Oral TabletSCDe8626e68-088d-47ff-bf06-489a778815aa12
283639olanzapine 20 MG Oral TabletSCDe8626e68-088d-47ff-bf06-489a778815aa12
312078olanzapine 5 MG Oral TabletSCDe8626e68-088d-47ff-bf06-489a778815aa12
312079olanzapine 7.5 MG Oral TabletSCDe8626e68-088d-47ff-bf06-489a778815aa12

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
67877-176-0167877017601100 TABLET in 1 BOTTLE (67877-176-01) 100 tablet2012-01-010000-00-00NoNoCurrent
67877-176-10678770176101000 TABLET in 1 BOTTLE (67877-176-10) 1000 tablet2012-01-010000-00-00NoNoCurrent
67877-176-306787701763030 TABLET in 1 BOTTLE (67877-176-30) 30 tablet2012-01-010000-00-00NoNoCurrent
67877-176-32678770176327 TABLET in 1 BOTTLE (67877-176-32) 7 tablet2012-01-010000-00-00NoNoCurrent
67877-176-336787701763310 in 1 BLISTER PACKHistorical
67877-176-356787701763510 BLISTER PACK in 1 CARTON (67877-176-35) / 10 TABLET in 1 BLISTER PACK (67877-176-33) 10 blister pack2012-01-010000-00-00NoNoCurrent
67877-176-85678770176853 BLISTER PACK in 1 CARTON (67877-176-85) / 10 TABLET in 1 BLISTER PACK (67877-176-33) 3 blister pack2012-01-010000-00-00NoNoCurrent